Introduction
Despite rhabdomyolysis is known as a potential etiology of Acute kidney injury in SARS-COV-2 patients, the burden of rhabdomyolysis in COVID-19 hospitalized patients is scarce. The objective of the present study was to assess the prevalence and risk factors of rhabdomyolysis in SARS-COVID-2 patients.
Methods
We conducted a serial case of COVID-19 patients attending the Kinshasa Medical’s Center from March, 25thto August 25th, 2020. Patients having stroke and myocardial infarction were excluded. Rhabdomyolysis was defined as a level of creatine kinase (CK) >1000UI/l. The clinical stage of COVID-19 was determined according to the WHO classification. Pearson's Khi square or Fisher exact test were used to compare proportions. The P value significance level was 0.05.
Results
93 COVID-19 patients were involved (58.5 ± 11.9 years, 73.5% male), among whom 28% were in the critical stage and 48% in the moderate stage. The prevalence of rhabdomyolysis was 12.9 %. Compared to patients without rhabdomyolysis, in those with rhabdomyolysis; the proportions of hypertension (75%vs. 54%, p= 0.049), diabetes (58% vs. 27%, p=0.041) and AKI (50% vs. 24%, p=0.001) were significantly higher. In addition, mean LDH values of patients having rhabdomyolysis were significantly elevated compared to patients without rhabdomyolysis.
Conclusions
Rhabdomyolysis is very common in Congolese COVID-19 patients. It is associated with kidney injury in half of cases.
No conflict of interest